Eisai and Merck announced that the U.S. FDA approved the kinase inhibitor Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Japan’s Eisai Co. Ltd. will price the company’s cancer drug Lenvima at about $16,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved the product’s use in patients with a common form of liver cancer.
Exclusive: U.S. health regulator Verma eyes new methods for drug pricing
Blood Cancers, Cancer, Centers for Medicare and Medicaid Services (CMS), Congress, Costs, Democrats, Department of Health and Human Services (HHS), Diseases, Gene Therapy, Government, Healthcare/Medicare/Medicaid, Liver Cancer, Lung Cancer, Prescription Drugs, Pricing, Republicans, TherapeuticsThe U.S. government is considering setting new payment methods aimed at curbing costs for Medicare and Medicaid coverage of breakthrough medical treatments with very high prices, particularly novel gene-based therapies for cancer and other diseases, a top health official said.
Shares of Onxeo were down more than 50 percent after the company’s Phase III liver cancer drug Livatag failed to improve survivability over standard of care.
The U.S. Food and Drug Administration said it approved Bayer AG’s drug Stivarga to treat liver cancer, the first such approval in nearly a decade.
The European Medicines Agency warned for the second time in 2016 that some of the top-selling hepatitis C treatments could reactivate hepatitis B in patients.
German drugmaker Bayer said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.
The EMA said it extended a safety review of chronic hepatitis C treatments after new data showed patients taking the drugs were at risk of their liver cancer returning.